Portfolio company Kate Therapeutics was acquired by Novartis for up to $1.1B including milestones.
Kate Therapeutics is a next-generation gene therapy company focused on developing innovative treatments for genetic skeletal muscle and heart diseases, including Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD)
Kate Therapeutics is a next-generation gene therapy company focused on developing innovative treatments for genetic skeletal muscle and heart diseases, including Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).